These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16990957)

  • 61. The role of inflammation for heart disease risk cannot be determined by correlations between C-reactive protein and risk factors.
    Engström G
    Arch Intern Med; 2006 May; 166(9):1040; author reply 1040-1. PubMed ID: 16682580
    [No Abstract]   [Full Text] [Related]  

  • 62. Ministry of health clinical practice guidelines: screening of cardiovascular disease and risk factors.
    Goh LG; Chua T; Kang V; Kwong KH; Lim WY; Low LP; Pereira J; Venketasubramanian N; Sethi SK; Sum CF; Tan CL; Tan HK; Tan SM; Wong TK;
    Singapore Med J; 2011 Mar; 52(3):220-5 quiz 226-7. PubMed ID: 21451932
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma.
    Donahue MP; Rose K; Hochstrasser D; Vonderscher J; Grass P; Chibout SD; Nelson CL; Sinnaeve P; Goldschmidt-Clermont PJ; Granger CB
    Am Heart J; 2006 Sep; 152(3):478-85. PubMed ID: 16923417
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Using nontraditional risk factors in coronary heart disease risk assessment.
    Lin KW; Garcia SM
    Am Fam Physician; 2011 Feb; 83(4):449. PubMed ID: 21322521
    [No Abstract]   [Full Text] [Related]  

  • 65. A tool for more accurate risk-prediction in acute coronary syndrome.
    Dis Manag Advis; 2005 Feb; 11(2):22-3, 13. PubMed ID: 15822370
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Cholesterol measurement as a screening test: a category error].
    Borgers D
    Z Arztl Fortbild Qualitatssich; 2003 Feb; 97(1):19-26. PubMed ID: 12669686
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Coronary artery calcium testing: dos and don'ts.
    Polonsky TS; Lloyd-Jones DM
    Cardiol Clin; 2012 Feb; 30(1):49-55. PubMed ID: 22304948
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lipoprotein complexed C-reactive protein in patients with coronary heart disease.
    Elmas E; Kälsch T; Borggrefe M; Dempfle CE
    Thromb Haemost; 2005 Nov; 94(5):1111-2. PubMed ID: 16363260
    [No Abstract]   [Full Text] [Related]  

  • 69. C-reactive protein concentrations are lower in Singaporeans: implications for risk classification in Asians.
    Hawkins RC
    Clin Chim Acta; 2004 Dec; 350(1-2):241-2. PubMed ID: 15530485
    [No Abstract]   [Full Text] [Related]  

  • 70. Mayo Clinic office visit. Testing C-reactive protein. An interview with Thomas Behrenbeck, M.D., Ph.D.
    Behrenbeck T
    Mayo Clin Womens Healthsource; 2010 Feb; 14(2):6. PubMed ID: 20048728
    [No Abstract]   [Full Text] [Related]  

  • 71. The USPSTF recommendation statement on coronary heart disease risk assessment.
    Blaha MJ; Campbell CY; Horne A
    Ann Intern Med; 2010 Mar; 152(6):404-5; author reply 405-6. PubMed ID: 20231578
    [No Abstract]   [Full Text] [Related]  

  • 72. The use of high sensitivity C-reactive protein in assessing the risk for coronary heart disease.
    Legrys VA
    Clin Lab Sci; 2001; 14(4):243-6. PubMed ID: 11760822
    [No Abstract]   [Full Text] [Related]  

  • 73. The SHAPE paradigm: a commentary.
    Shah PK
    Circ Cardiovasc Qual Outcomes; 2010 Jan; 3(1):106-9. PubMed ID: 20123677
    [No Abstract]   [Full Text] [Related]  

  • 74. American Heart Association guidelines for prevention of pediatric cardiovascular disease.
    Kash IJ
    J Pediatr; 2004 Apr; 144(4):552; author reply 552-3. PubMed ID: 15069413
    [No Abstract]   [Full Text] [Related]  

  • 75. Medical screening and the value of early detection. When unwarranted faith leads to unethical recommendations.
    Malm HM
    Hastings Cent Rep; 1999; 29(1):26-37. PubMed ID: 10052009
    [No Abstract]   [Full Text] [Related]  

  • 76. How to prevent 500,000 heart attacks a year. Widespread screening for CVD could pinpoint who's vulnerable.
    Duke Med Health News; 2006 Nov; 12(11):1, 11. PubMed ID: 17225301
    [No Abstract]   [Full Text] [Related]  

  • 77. Risk marker may play key role in heart disease.
    Health News; 2005 Mar; 11(3):2. PubMed ID: 15803566
    [No Abstract]   [Full Text] [Related]  

  • 78. Developing a local protocol for the management of lipid disorders in general practice.
    Foster KN; Bain NS; Grimshaw JM; MacLeod TN; Broom J; Reid J; Ritchie LD
    Health Bull (Edinb); 1996 May; 54(3):270-5. PubMed ID: 8707572
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inflammatory markers are useful risk assessment tools.
    Libby P
    Am J Manag Care; 2003 Aug; Suppl():6-7. PubMed ID: 13678397
    [No Abstract]   [Full Text] [Related]  

  • 80. Diagnosis and treatment of non-hemodynamically significant coronary heart disease: where to start?
    Runge MS; Subramanian N; Stouffer GA
    Trans Am Clin Climatol Assoc; 2005; 116():273-80; discussion 281. PubMed ID: 16555620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.